Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11628150 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(6 years from now) | |
US11020361 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(6 years from now) | |
US8334281 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
May, 2030
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jun 19, 2023 |
Market Authorisation Date: 19 June, 2020
Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis
Dosage: SPRAY, METERED;NASAL
10
United States
3
Canada
1
Poland
1
Spain
1
Portugal
1
Denmark
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic